Criteria Changes for Subsequent Dosing of Palivizumab (Synagis) with Fall/Winter Traditional Respiratory Syncytial Virus Season
For additional information, click here.
* Required field
ATTENTION: By clicking Continue, you will leave the FirstCare Medicare Advantage pages. If you want to remain on these pages, click Cancel or close this box.